|
|
|
|
|
Sponsors and Collaborators: |
Amylin Pharmaceuticals, Inc. Eli Lilly and Company |
Information provided by: | Amylin Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT00082407 |
This is a Phase 3, multicenter, open-label, comparator-controlled trial.
Condition | Intervention | Phase |
Diabetes Mellitus, Type 2 |
Drug: AC2993 |
Phase III |
MedlinePlus related topics: | Diabetes |
ChemIDplus related topics: | Insulin Exenatide Insulin aspart Metformin Metformin hydrochloride |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Efficacy of Exenatide (AC2993, Synthetic Exendin-4, LY2148568) Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin |
Ages Eligible for Study: | 30 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Show 71 Study Locations |
Amylin Pharmaceuticals, Inc. |
Eli Lilly and Company |
Link to study results on ClinicalStudyResults.org 
  |
Study ID Numbers: | H8O-MC-GWAD |
First Received: | May 6, 2004 |
Last Updated: | November 5, 2007 |
ClinicalTrials.gov Identifier: | NCT00082407 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|